Overview
Cyclic guanosine monophosphate (cGMP) signaling is a cellular communication pathway in which the second messenger molecule cGMP regulates various physiological processes, particularly those involving smooth muscle relaxation, vasodilation, and cardiac function. In the context of heart failure and cardiorenal interactions, cGMP signaling plays a critical role in modulating blood pressure, fluid balance, and cardiac remodeling. Research published in this journal examines how cardiorenal signaling pathways, including those mediated by cGMP, function in heart failure states. The natriuretic peptide system, which activates cGMP production through particulate guanylate cyclase receptors, represents a key mechanism by which the heart and kidneys communicate to maintain cardiovascular homeostasis. Understanding both the beneficial and detrimental aspects of these signaling cascades is essential for developing therapeutic strategies in heart failure management. The cGMP pathway intersects with multiple regulatory systems that influence vascular tone, sodium excretion, and myocardial contractility, making it a central focus in Hypertension and Cardiology research. Disruptions in cGMP signaling contribute to the pathophysiology of cardiovascular disease, highlighting the importance of this molecular pathway in both normal physiology and disease states.
Research published in this journal
1 peer-reviewed article, ranked by relevance. Each links to its DOI.
How this research is being cited
The 1 article above has been cited 1 time in the scholarly literature. Citation data via OpenAlex and Crossref, updated Oct 2025.
-
2016 · Journal of Hypertension and Cardiology
A sample of recent works citing this journal's research on Cgmp Signaling, linking to each citing work.